Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28532691
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Adv+Drug+Deliv+Rev
2017 ; 114
(ä): 266-271
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Bio-synthetic materials for immunomodulation of islet transplants
#MMPMID28532691
Foster GA
; García AJ
Adv Drug Deliv Rev
2017[May]; 114
(ä): 266-271
PMID28532691
show ga
Clinical islet transplantation is an effective therapy in restoring physiological
glycemic control in type 1 diabetics. However, allogeneic islets derived from
cadaveric sources elicit immune responses that result in acute and chronic islet
destruction. To prevent immune destruction of islets, transplant recipients
require lifelong delivery of immunosuppressive drugs, which are associated with
debilitating side effects. Biomaterial-based strategies to eliminate the need for
immunosuppressive drugs are an emerging therapy for improving islet
transplantation. In this context, two main approaches have been used: 1)
encapsulation of islets to prevent infiltration and contact of immune cells, and
2) local release of immunomodulatory molecules from biomaterial systems that
suppress local immunity. Synthetic biomaterials provide excellent control over
material properties, molecule presentation, and therapeutic release, and thus,
are an emerging platform for immunomodulation to facilitate islet
transplantation. This review highlights various synthetic biomaterial-based
strategies for preventing immune rejection of islet allografts.
|*Immunomodulation
[MESH]
|Animals
[MESH]
|Biocompatible Materials/*therapeutic use
[MESH]
|Graft Rejection/immunology/*prevention & control
[MESH]